Sapient Capital LLC Cuts Position in Liquidia Co. (NASDAQ:LQDA)

Sapient Capital LLC cut its stake in Liquidia Co. (NASDAQ:LQDA) by 8.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 122,200 shares of the company’s stock after selling 11,400 shares during the period. Sapient Capital LLC owned about 0.14% of Liquidia worth $1,437,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after acquiring an additional 123,402 shares in the last quarter. Barclays PLC grew its position in Liquidia by 265.0% in the third quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after acquiring an additional 72,591 shares in the last quarter. Whitefort Capital Management LP grew its position in Liquidia by 119.8% in the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after acquiring an additional 927,546 shares in the last quarter. JPMorgan Chase & Co. grew its position in Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after acquiring an additional 210,753 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after acquiring an additional 230,820 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Trading Up 0.2 %

Liquidia stock opened at $16.26 on Wednesday. The firm has a 50-day moving average of $12.55 and a 200-day moving average of $11.32. The firm has a market cap of $1.38 billion, a P/E ratio of -9.98 and a beta of 0.27. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $16.99.

Insider Transactions at Liquidia

In other news, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the transaction, the insider now directly owns 267,943 shares of the company’s stock, valued at approximately $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,945 shares of company stock worth $874,403. Company insiders own 30.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on LQDA. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. Scotiabank assumed coverage on shares of Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).